Differential metabolic effects of distinct statins

Atherosclerosis

Volumn 215, Issue 1, 2011, Pages 1-8

  Koh, Kwang Kon ^a   Sakuma, Ichiro ^b   Quon, Michael J ^c  

^a Gachon University College of Medicine   (South Korea)

^b Hokko Memorial Hospital   (Japan)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Diabetes; Insulin resistance; Statins

Indexed keywords

ADIPONECTIN; ATORVASTATIN; CANDESARTAN; EFONIDIPINE; FENOFIBRATE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HORMONE SYNTHESIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK REDUCTION;

ADIPONECTIN; ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; FLUOROBENZENES; HEPTANOIC ACIDS; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; MICE; PRAVASTATIN; PYRIMIDINES; PYRROLES; SIMVASTATIN; SULFONAMIDES;

EID: 79952106340     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.036     Document Type: Review

References (74)

1. Sacks F.M., Tonkin A.M., Shepherd J., et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. Circulation 2000, 102:1893-1900.
2. Han S.H., Quon M.J., Koh K.K. Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction. Curr Opin Lipidol 2007, 18:58-65.
3. Muniyappa R., Montagnani M., Koh K.K., Quon M.J. Cardiovascular actions of insulin. Endocr Rev 2007, 28:463-491.
4. Kim J., Montagnani M., Koh K.K., Quon M.J. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006, 113:1888-1904.
5. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657.
6. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003, 348:1625-1638.
7. Beckman J.A., Creager M.A., Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002, 287:2570-2581.
8. Freeman D.J., Norrie J., Sattar N., et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103:357-362.
9. Sasaki J., Iwashita M., Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006, 13:123-129.
10. Yada T., Nakata M., Shiraishi T., Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999, 126:1205-1213.
11. Kanda M., Satoh K., Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003, 26:1681-1684.
12. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001, 507:357-361.
13. Nakata M., Nagasaka S., Kusaka I., et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic control. Diabetologia 2006, 49:1881-1892.
14. Wong V., Stavar L., Szeto L., et al. Atorvastatin induces insulin sensitization in Zucker lean and fatty rats. Atherosclerosis 2006, 184:348-355.
15. Tesfamariam B., Frohlich B.H., Gregg R.E. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol 1999, 34:95-101.
16. Ishikawa M., Okajima F., Inoue N., et al. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells. J Atheroscler Thromb 2006, 13:329-335.
17. Takagi T., Matsuda M., Abe M., et al. Effect of pravastatin on the development of diabetes and adiponectin production. Atherosclerosis 2008, 196:114-121.
18. McTaggart F., Buckett L., Davidson R., et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001, 87(5A):28B-32B.
19. Farrer M., Winocour P.H., Evans K., et al. Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994, 23:111-119.
20. Ohrvall M., Lithell H., Johansson J., Vessby B. A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism 1995, 44:212-217.
21. Paolisso G., Barbagallo M., Petrella G., et al. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis 2000, 150:121-127.
22. Altunbaş H., Balci M.K., Karayalçin U. No effect of simvastatin treatment on insulin sensitivity in patients with primary hypercholesterolemia. Endocr Res 2003, 29:265-275.
23. Devaraj S., Siegel D., Jialal I. Simvastatin (40mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol 2007, 100:1397-1399.
24. Jula A., Marniemi J., Huupponen R., et al. Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial. JAMA 2002, 287:598-605.
25. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
26. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005, 45:1088-1093.
27. Han S.H., Quon M.J., Kim J.A., Koh K.K. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol 2007, 49:531-538.
28. Han S.H., Sakuma I., Shin E.K., Koh K.K. Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. Prog Cardiovasc Dis 2009, 52:126-140.
29. Koh K.K., Han S.H., Quon M.J., Ahn J.Y., Shin E.K. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
30. Koh K.K., Quon M.J., Han S.H., et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006, 108:96-100.
31. Koh K.K., Quon M.J., Lee S.J., et al. Efonidipine simultaneously improves blood pressure, endothelial function, and metabolic parameters in non-diabetic patients with hypertension. Diabetes Care 2007, 30:1605-1607.
32. Katz A., Nambi S.S., Mather K., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
33. Chen H., Sullivan G., Quon M.J. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 2005, 54:1914-1925.
34. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab 2008, 294:E15-26.
35. Koh K.K., Quon M.J., Han S.H., et al. Simvastatin improves flow-mediated dilation, but reduces adiponectin levels and insulin sensitivity in hypercholesterolemic patients. Diabetes Care 2008, 31:776-782.
36. Forst T., Pfützner A., Lübben G., et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk-the PIOSTAT Study. Metabolism 2007, 56:491-496.
37. Koh K.K., Quon M.J., Han S.H., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009, 204:483-490.
38. Watts G.F., Barrett P.H., Ji J., et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 2003, 52:803-811.
39. Chan D.C., Watts G.F., Barrett P.H., Beilin L.J., Mori T.A. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem 2002, 48(6 Pt 1):877-883.
40. Stalenhoef A.F., Ballantyne C.M., Sarti C., et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005, 26:2664-2672.
41. Costa A., Casamitjana R., Casals E., et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 2003, 20:743-745.
42. Huptas S., Geiss H.C., Otto C., Parhofer K.G. Effect of atorvastatin (10mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006, 98:66-69.
43. Nakamura T., Kodama Y., Takano H., et al. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. Atherosclerosis 2007, 193:449-451.
44. von Eynatten M., Liu D., Bluemm A., et al. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. Clin Endocrinol (Oxf) 2009, 71:27-32.
45. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of patients with combined hyperlipidemia. J Am Coll Cardiol 2005, 45:1649-1653.
46. Koh K.K., Quon M.J., Han S.H., et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010, 55:1209-1216.
47. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141:421-431.
48. Gerstein H.C., Pogue J., Mann J.F., et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 2005, 48:1749-1755.
49. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321:405-412.
50. ter Avest E., Abbink E.J., de Graaf J., Tack C.J., Stalenhoef A.F. Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest 2005, 35:558-564.
51. Chan P., Tomlinson B., Lee C.B., Pan W.H., Lee Y.S. Beneficial effects of pravastatin on fasting hyperinsulinemia in elderly hypertensive hypercholesterolemic subjects. Hypertension 1996, 28:647-651.
52. Guclu F., Ozmen B., Hekimsoy Z., Kirmaz C. Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome. Biomed Pharmacother 2004, 58:614-618.
53. Sugiyama S., Fukushima H., Kugiyama K., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-51.
54. Gannage-Yared M.H., Azar R.R., Amm-Azar M., et al. Pravastatin does not affect insulin sensitivity and adipocytokines levels in healthy nondiabetic patients. Metabolism 2005, 54:947-951.
55. Correia M.L., Haynes W.G. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens 2004, 13:215-223.
56. Koh K.K., Park S.M., Quon M.J. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation 2008, 117:3238-3249.
57. Ishikawa M., Namiki A., Kubota T., et al. Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia. Intern Med 2006, 45:51-55.
58. Mita T., Watada H., Nakayama S., et al. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. Endocr J 2007, 54:441-447.
59. Ando H., Sugimoto K., Yanagihara H., et al. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clin Exp Pharmacol Physiol 2008, 35:1012-1017.
60. Baker W.L., Talati R., White C.M., Coleman C.I. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract 2010, 87:98-107.
61. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
62. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
63. Sabatine M.S., Wiviott S.D., Morrow D.A., et al. High-dose atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy. Circulation 2004, 110(Supplement III-834). [abstract].
64. Shepherd J., Barter P., Carmena R., et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes. The treating to new targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
65. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195-2207.
66. Kjekshus J., Apetrei E., Barrios V., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
67. Keech A., Colquhoun D., Best J., et al. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care 2003, 26:2713-2721.
68. Jick S.S., Bradbury B.D. Statins and newly diagnosed diabetes. Br J Clin Pharmacol 2004, 58:303-309.
69. Rajpathak S.N., Kumbhani D.J., Crandall J., et al. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009, 32:1924-1929.
70. Coleman C.I., Reinhart K., Kluger J., White C.M. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008, 24:1359-1362.
71. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
72. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
73. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222. The Emerging Risk Factors Collaboration.
74. Gerstein H.C. More insights on the dysglycaemia-cardiovascular connection. Lancet 2010, 375:2195-2196.